- Updated indication allows the use of RINVOQ ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom use of these treatments is clinically inadvisable ...
AbbVie has reached settlements with all generic drugmakers to resolve litigation that challenged their plans to introduce generics of its arthritis drug Rinvoq, per an MSN report. The generic drug ...
NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ ® (upadacitinib), 15 mg, once daily, for the treatment ...
NORTH CHICAGO, Ill., Oct. 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from two replicate Phase 3 studies evaluating the safety and efficacy of upadacitinib ...
MedPage Today on MSN
Not All Drugs Approved for Rheumatoid Arthritis Are Equal for Pain Relief
Trial data suggest a JAK inhibitor beats the leading biologic ...
NORTH CHICAGO, Ill., Aug. 21, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the second of two pivotal studies of the Phase 3 UP-AA clinical program evaluating ...
(RTTNews) - AbbVie's (ABBV) autoimmune drug Rinvoq has successfully met the endpoints in two replicate phase 3 studies in adult and adolescent patients with non-segmental vitiligo. Non-segmental ...
Both Skyrizi and its cousin Rinvoq have landed in the annual top three, in varying positions, since 2022. That was once again the case in 2025, when Skyrizi retained its place at the top and Rinvoq ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback